KeyBanc Capital Markets Adjusts Price Target on Codex DNA to $5 From $8, Maintains Overweight Rating
MT NewswiresNov 9, 2022 09:43 ET
Codex DNA Analyst Ratings
Benzinga Analyst RatingsNov 9, 2022 04:51 ET
Keybanc Maintains Overweight on Codex DNA, Lowers Price Target to $5
Benzinga Real-time NewsNov 9, 2022 04:51 ET
No Data
No Data